Coherus Oncology Change in Accounts Receivable 2013-2025 | CHRS

Coherus Oncology change in accounts receivable from 2013 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Coherus Oncology Change in Accounts Receivable 2013-2025 | CHRS

Coherus Oncology change in accounts receivable from 2013 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$248.3B
Amgen (AMGN)$155.9B
Gilead Sciences (GILD)$142.4B
Vertex Pharmaceuticals (VRTX)$99.3B
Bristol Myers Squibb (BMY)$96.1B
GSK (GSK)$81.1B
CSL (CSLLY)$67.7B
Regeneron Pharmaceuticals (REGN)$62.3B
Alnylam Pharmaceuticals (ALNY)$59.1B
Argenex SE (ARGX)$43.3B
Insmed (INSM)$27.9B
BioNTech SE (BNTX)$25.2B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.4B
Genmab (GNMSF)$16B
Genmab (GMAB)$15.7B
Illumina (ILMN)$15.2B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$11B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.3B
Moderna (MRNA)$9.6B
Verona Pharma American Depositary Share (VRNA)$9.1B
Bio-Techne Corp (TECH)$8.9B
Exact Sciences (EXAS)$8.7B
Halozyme Therapeutics (HALO)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B